facebook
twitter
rss
account
search
search
 

FDA approves new fibrillation drug

July 2, 2009 at 11:10 AM   |   Comments

WASHINGTON, July 2 (UPI) -- The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.

The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

Since Multaq might cause critical adverse reactions, including death, in patients with recent severe heart failure, officials said Multag's drug's label will contain a boxed warning, the FDA's strongest warning, cautioning the drug should not be used by such people.

Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.

© 2009 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Next week's lunar eclipse may feature the color turquoise Next week's lunar eclipse may feature the color turquoise
2
"Man in the moon" likely caused by volcano, not astroid "Man in the moon" likely caused by volcano, not astroid
3
Apple releases fix for 'Shellshock' virus Apple releases fix for 'Shellshock' virus
4
Social network Ello getting thousands of requests per hour Social network Ello getting thousands of requests per hour
5
35,000 walruses haul out of ocean, crowd Alaskan shore 35,000 walruses haul out of ocean, crowd Alaskan shore
Trending News
x
Feedback